Bronze
Lonza
Lonza is propelling cell and gene therapy forward through its pioneering technologies and solutions. Our Nucleofector technology facilitates efficient and adaptable cell transfection, crucial for gene editing and therapy endeavours. Meanwhile, the Cocoon platform automates and refines cell therapy manufacturing, presenting a scalable, closed-system solution for personalized treatments. Lonza is committed to refining processes to hasten the development and production of these therapies. Our tailored services and top-notch facilities, equipped with scalable platforms and automated systems, bolster efficient manufacturing. Lonza's innovations expedite the journey from research to market, ultimately reducing costs and broadening patient access to state-of-the-art treatments.
Novartis
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global healthcare company, it seeks to deliver transformative treatments by pushing the boundaries of medical paradigms and exploring possibilities to cure disease, intervening earlier in chronic illnesses and finding ways to exponentially enhance quality of life.
Having pioneered CAR-T cell therapy as an approved treatment for B-cell malignancies, Novartis remains committed to building on this innovation in CAR-T cell therapy and beyond, researching its CAR-T cell therapy in various clinical trials and constantly seeking new platforms to expand into new areas.
STEMCELL
As a company of Scientists Helping Scientists, STEMCELL Technologies is committed to enabling cell and gene therapy research around the world with high-quality services and solutions. Whether you're editing CD34+ cells, differentiating PSCs, or expanding immune cells, we have over 2500 specialized cell isolation products, cell culture media, and reagents to help you get therapies to patients faster. Our ethically sourced human primary cell portfolio includes cryopreserved products from peripheral blood such as diseased PBMCs, cord blood, and bone marrow. Start your experiments with the right cells by exploring our range of primary and cultured cells.
Learn more here.
InnoCellular
At the forefront of advancing therapeutic technologies, InnoCellular specializes in developing efficient and cost-effective cell culture media for stem cells and specialized cell applications. Renowned for our expertise, we excel in formulating high-performance, consistent, and top-quality biological products essential for pioneering next-generation therapies. Our services encompass a diverse array of options, from ready-to-use or basal formulations, designed for research-only or cGMP purposes, all tailored with unparalleled flexibility to meet your specific experimental or clinical needs.
To read more, visit here.
Singleron
Singleron helps advance cell and gene therapy research by unravelling
cellular heterogeneity. Our products and services aid researchers in identifying
therapeutic targets, characterizing cell therapy products, tracking treatment
outcomes, and revealing mechanisms for differential therapeutic responses.
From tissue dissociation to specialized single cell multi-omic methods
to advanced machine learning models, we have a solution that will meet
your needs. As Singapore's longest-standing commercial single cell service
provider, our expert team collaborates closely with you to ensure project
success.
Choose Singleron for all your single cell analysis needs. Let us help
accelerate your research and unlock its full potential, click here.
SGS
With over 35 years’ experience as a global contract service organization, SGS provides integrated (bio)pharmaceutical development and testing solutions including clinical research, pharmaceutical development, biologics characterization, biosafety, and quality control testing for small and large molecules, raw materials, containers and finished products.
SGS provides a comprehensive range of biosafety services such as: virology, cell and molecular biology, microbiology and TEM. Health Authorities (US FDA and the EMA), require companies to undergo safety testing demonstrating that cell banks, viral banks, raw materials, bulk harvests, and batches of clinical drug are free of bacteria, fungi, mycoplasma, viruses and other potential contaminants. SGS ensures product safety in satisfying these regulatory requirements.